Phenobarbital Bioequivalence in Chinese Population: Considering the Role of Food on Pharmacokinetics
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1604 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Wang Xinman und 3 weiteren Autor:innen. Beteiligte Einrichtung: ZiBo 148 Hospital, China RongTong Medical Healthcare Group Co., Ltd., Zibo, Shandong, China. Hauptthemen laut MEDLINE: Phenobarbital, Anticonvulsants, Drugs, Generic, Food-Drug Interactions. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Epilepsy is one of the most severe neurological disorders in the world, which might seriously endanger the lives of patients. Phenobarbital is an important medicine clinically used for the treatment of epilepsy, and it is irreplaceable in the treatment of generalized tonic–clonic seizures, focal seizures, status epilepticus, and pediatric epilepsy. However, the original research medicine of phenobarbital has not been launched in China. Therefore, an economical and effective generic medicine is of great significance to patients. In this study, a single‐center, randomized, open‐label, single‐dose, two‐formulation, two‐period, two‐sequence crossover design and parallel design were adopted. The phenobarbital tablets produced by Shandong Xinhua Pharmaceutical Co., Ltd. were used as the test formulation, and Phenobal produced by Fujinaga Pharmaceutical Co., Ltd. was used as the reference formulation for a bioequivalence study. Additionally, the influence of food on the pharmacokinetic parameters al was investigated. The results showed that the test formulation and the reference formulation were bioequivalent, and food might reduce the C max (maximum concentration) and exposure of phenobarbital. This study provides data support for the marketing of generic phenobarbital medicines and offers a theoretical basis for the rational administration of phenobarbital. The clinical trial was registered in Chinese Clinical Trial Registry (Registration numbers: CTR20242404 and CTR20244155).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ZiBo 148 Hospital, China RongTong Medical Healthcare Group Co., Ltd., Zibo, Shandong, China.
- Shandong Xinhua Pharmaceutical Co., Ltd., Zibo, China.
Zitieren
APA
Xinman, W., Yuan, L., Ying, S., & Yiyun, W. (2025). Phenobarbital Bioequivalence in Chinese Population: Considering the Role of Food on Pharmacokinetics. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1604
Vancouver
Xinman W, Yuan L, Ying S, Yiyun W. Phenobarbital Bioequivalence in Chinese Population: Considering the Role of Food on Pharmacokinetics. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1604
BibTeX
@article{Xinman2025,
author = {Xinman, Wang and Yuan, Liu and Ying, Sun and Yiyun, Wang},
title = {Phenobarbital Bioequivalence in Chinese Population: Considering the Role of Food on Pharmacokinetics},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1604}
}
EUVIMED